Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2020 Filed Feb 14, 2020 22:07 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
SaleCommon Stock | 103 | $188.49 | $19,414.47 |
DisclosureSEC source: 0001127602-20-005713 · form4.xml · nonDerivative · entry 6 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486.3565 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 22:07 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
SaleCommon Stock | 85 | $188.49 | $16,021.65 |
DisclosureSEC source: 0001127602-20-005713 · form4.xml · nonDerivative · entry 5 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589.3565 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 20:08 UTC |
Williams R SandersDirector
|
SaleCommon Stock | 1,227 | $188.49 | $231,277.23 |
DisclosureSEC source: 0001127602-20-005587 · form4.xml · nonDerivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,095 F2 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:09 UTC |
Parham Richelle PDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005589 · form4.xml · derivative · entry 2 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986 Underlying: Common Stock · 1,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2020. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:09 UTC |
Parham Richelle PDirector
|
Exercise / conversionCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005589 · form4.xml · nonDerivative · entry 1 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:32 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 940 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005749 · form4.xml · derivative · entry 6 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,650 Underlying: Common Stock · 940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:32 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 780 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005749 · form4.xml · derivative · entry 5 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,590 Underlying: Common Stock · 780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:32 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 280 | $187.51 | $52,502.80 |
DisclosureSEC source: 0001127602-20-005749 · form4.xml · nonDerivative · entry 4 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,966 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:32 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005749 · form4.xml · nonDerivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:32 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 232 | $187.51 | $43,502.32 |
DisclosureSEC source: 0001127602-20-005749 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,306 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:32 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005749 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
Exercise / conversionRestricted Stock Unit · Derivative | 283 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · derivative · entry 8 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Underlying: Common Stock · 283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F6 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
Exercise / conversionRestricted Stock Unit · Derivative | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · derivative · entry 7 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,040 Underlying: Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
Tax withholdingCommon Stock | 78 | $187.51 | $14,625.78 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,943.8788 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
Exercise / conversionCommon Stock | 283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,021.8788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
Tax withholdingCommon Stock | 80 | $187.51 | $15,000.80 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,738.8788 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC |
van der Vaart Sandra DSVP, Global General Counsel
|
Exercise / conversionCommon Stock | 290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,818.8788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:07 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionRestricted Stock Unit · Derivative | 283 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005713 · form4.xml · derivative · entry 8 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,511 Underlying: Common Stock · 283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F6 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:07 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionRestricted Stock Unit · Derivative | 233 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005713 · form4.xml · derivative · entry 7 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,794 Underlying: Common Stock · 233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:07 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 78 | $187.51 | $14,625.78 |
DisclosureSEC source: 0001127602-20-005713 · form4.xml · nonDerivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674.3565 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:07 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionCommon Stock | 283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005713 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752.3565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:07 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 64 | $187.51 | $12,000.64 |
DisclosureSEC source: 0001127602-20-005713 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469.3565 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:07 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionCommon Stock | 233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005713 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 533.3565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:11 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 353 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005619 · form4.xml · derivative · entry 9 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,768 Underlying: Common Stock · 353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:11 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005619 · form4.xml · derivative · entry 8 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,121 Underlying: Common Stock · 2,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:11 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 233 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005619 · form4.xml · derivative · entry 7 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,474 Underlying: Common Stock · 233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:11 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Tax withholdingCommon Stock | 105 | $187.51 | $19,688.55 |
DisclosureSEC source: 0001127602-20-005619 · form4.xml · nonDerivative · entry 6 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,358 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:11 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Exercise / conversionCommon Stock | 353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005619 · form4.xml · nonDerivative · entry 5 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:11 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Tax withholdingCommon Stock | 699 | $187.51 | $131,069.49 |
DisclosureSEC source: 0001127602-20-005619 · form4.xml · nonDerivative · entry 4 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,110 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:11 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Exercise / conversionCommon Stock | 2,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005619 · form4.xml · nonDerivative · entry 3 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:11 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Tax withholdingCommon Stock | 68 | $187.51 | $12,750.68 |
DisclosureSEC source: 0001127602-20-005619 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,456 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:11 UTC |
BERBERIAN LANCESVP, Chief Information Officer
|
Exercise / conversionCommon Stock | 233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005619 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · SVP, Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:07 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005615 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,540 Underlying: Common Stock · 1,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2020. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:07 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005615 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:51 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005604 · form4.xml · derivative · entry 9 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,188 Underlying: Common Stock · 2,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F6 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:51 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 283 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005604 · form4.xml · derivative · entry 8 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,541 Underlying: Common Stock · 283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F6 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:51 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 233 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005604 · form4.xml · derivative · entry 7 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,824 Underlying: Common Stock · 233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:51 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 698 | $187.51 | $130,881.98 |
DisclosureSEC source: 0001127602-20-005604 · form4.xml · nonDerivative · entry 6 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326.3903 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 105.4961 shares acquired on June 28, 2019 and 66.8942 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:51 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 2,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005604 · form4.xml · nonDerivative · entry 5 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,024.3903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 105.4961 shares acquired on June 28, 2019 and 66.8942 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:51 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 86 | $187.51 | $16,125.86 |
DisclosureSEC source: 0001127602-20-005604 · form4.xml · nonDerivative · entry 4 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671.3903 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 105.4961 shares acquired on June 28, 2019 and 66.8942 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:51 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005604 · form4.xml · nonDerivative · entry 3 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 757.3903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 105.4961 shares acquired on June 28, 2019 and 66.8942 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:51 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 82 | $187.51 | $15,375.82 |
DisclosureSEC source: 0001127602-20-005604 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474.3903 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 105.4961 shares acquired on June 28, 2019 and 66.8942 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:51 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005604 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556.3903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 105.4961 shares acquired on June 28, 2019 and 66.8942 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:50 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005603 · form4.xml · derivative · entry 6 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,184 Underlying: Common Stock · 680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:50 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 186 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005603 · form4.xml · derivative · entry 5 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,864 Underlying: Common Stock · 186 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:50 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 206 | $187.51 | $38,627.06 |
DisclosureSEC source: 0001127602-20-005603 · form4.xml · nonDerivative · entry 4 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:50 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005603 · form4.xml · nonDerivative · entry 3 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:50 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 66 | $187.51 | $12,375.66 |
DisclosureSEC source: 0001127602-20-005603 · form4.xml · nonDerivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:50 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005603 · form4.xml · nonDerivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 20:48 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 316 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005602 · form4.xml · derivative · entry 6 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,618 Underlying: Common Stock · 316 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.